Effects of hospitalization on functional status and health-related quality of life of patients with COVID-19 complications: a literature review

Miríã C. Oliveira¹, Marilúcia M. Carrió¹, João Pedro R. Afonso¹, Ricardo S. Moura¹, Luís Filipe R. J. Oliveira¹, Adriano L. Fonseca¹, Vinicio V. C. B. Melo², Maria Eduarda M. Lino², Beatriz N. Sousa², Elisangéla R. P. Póvoa², Shayra K. A. Souza², Thays L. Guedes², Larissa R. Alves¹, Rodolfo P. Vieira¹, Luís V. F. Oliveira¹

¹Stricto Sensu Post-Graduate Program in Human Movement and Rehabilitation, Evangelical University of Goiás, Anápolis-GO. ²Scientific Initiation Program, Evangelical University of Goiás, Anápolis-GO.

ABSTRACT

Background: Due to the clinical situations faced, patients with COVID-19 who survive the intensive care unit (ICU) are at greater risk of developing post-intensive care syndrome (PICS), characterized by typical physical, psychological and cognitive consequences in the post hospital discharge. Given this situation, it is important to assess these patients for the presence of musculoskeletal and psychosocial changes, so that they are referred to an outpatient and/or home rehabilitation program. Objective: to identify in the scientific literature the effects of hospitalization on the functional status and health-related quality of life of patients with complications from COVID-19. Methods: Searches were performed for scientific articles indexed in the MEDLINE database (accessed by Pubmed), between the years 2019 to 2022. Articles that met the inclusion and exclusion criteria determined to compose this study were included. Results: from a total of 524 articles found in the literature, only 15 met the inclusion criteria and were included in the study. The sample was represented by eight cross-sectional studies and seven cohort studies, and the main outcomes found to assess functional status were the six minute walking test the Post-COVID-19 Functional Status scale and for quality of life the EuroQol visual analogue scale and the Short form-36. Conclusion: With this literature review, it can be concluded that patients hospitalized for complications of COVID-19 showed a significant decline in functional status and health-related quality of life. However, updates are necessary to characterize the symptoms and persistent sequelae in the post-COVID-19. Keywords: COVID-19; Intensive care units; Post-intensive care syndrome; Functional status; Health-related quality of life.

BACKGROUND

Social distancing, isolation and long periods of hospitalization compromise the homeostasis of the human body, especially in an intensive care unit (ICU)¹,². Prolonged hospital stay causes a large percentage of surviving patients to develop significant complications and, depending on personal genotypes, symptoms may reflect immunological alterations³,⁴. In this context, the post-intensive care syndrome (PICS) is characterized by physical, psychological and cognitive consequences present after discharge from the ICU and which can last for 5 to 15 years⁵-⁷.

Data prior to the pandemic already showed that at least 20% of patients who were admitted to ICU and about 50% of these underwent mechanical ventilation (MV) develop PICS⁸. Patients with COVID-19 show that this incidence has increased dramatically, with a range of 28-87% of cases related to physical damage, 6-60% related to psychological changes and about 20-57% presented cognitive damage 1 to 6 months after discharge from ICU⁹.

The clinical profile of patients who develop PICS is similar to that of patients infected with COVID-19 who are admitted to the ICU, considering that most are older people and have at least one comorbidity¹⁰-¹². Among the main risk factors for the development of PICS, MV, prolonged immobility, acute respiratory distress syndrome (ARDS), use of neuromuscular blockers, use of corticosteroids, hyperglycemia, delirium, sepsis, renal failure and multiple organ failure⁶,⁹. Physical impairment, one of the main components of PICS, is present in 25 to 80% of patients hospitalized for long periods in the ICU. Acquired muscle weakness, fatigue, dyspnea, decreased lung function, compromised exercise tolerance, respiratory failure, sexual dysfunction, myopathies and neuropathies are also observed, which constantly lead to a decline in activities of daily living (ADL’s) and considerable quality impairment of life⁶,¹³-¹⁸. The scientific literature shows that ICU-acquired weakness (ICUAW) has a multifactorial etiology, being a growing problem in hospitalized patients, mainly with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), directly compromising the musculoskeletal system¹⁹-²⁰. During the hospitalization phase, the metabolic alterations are responsible for the increase in the involvement of the striated muscles, presenting themselves in diffuse and symmetrical patterns²¹. The presence of an inflammatory condition is linked to immobility, which is greater in this phase. The disuse of the limbs, especially the lower ones, caused by prolonged physical inactivity causes the individual to lose functionality²². Due to the period of hospitalization, the muscles do not receive mechanical discharges, with

¹Corresponding author: Miríã Cândida Oliveira; miriacandidaoliveira@gmail.com
Submission date 02 March 2022; Acceptance date 01 April 2022; Publication date 05 April 2022

Manual Therapy, Posturology & Rehabilitation Journal. ISSN 2236-5435. Copyright © 2020. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction in any medium provided article is properly cited
this a reduction in neuromuscular activity is observed, inducing an adaptive reaction characterized by slow protein synthesis, increased protein degradation and apoptosis of muscle cells, triggering a reduction in the volume and number of fibers and consequent loss of muscle strength, mainly in the muscles of the lower limbs (LL)(1).

Patients with COVID-19 who survive hospitalization in ICUs may be at even greater risk of developing PICS due to the restrictions they face, so it is extremely important that these patients are evaluated for the extent of possible physical, psychological and cognitive impairments(5,9,23). Using the ICU daily check sheet and the ABCDEF bundle (daily pain assessment, analgesia, breathing tests and spontaneous awakening, sedation, delirium, early mobility and family involvement) is a way to prevent PICS complications, although the component of the ABCDEF bundle is not sufficiently provided (16-52%) due to the highly transmissible nature of the virus(24). This guide was designed, based on evidence, to direct treatment within the ICU and thereby reduce the risk of subsequent hospitalizations, in addition to the excessive health-related costs of outpatient consultations(24,25).

In view of the impairments caused by COVID-19 and the prolonged period of hospitalization, the rehabilitation of patients who were affected by the virus should start at hospital admission and continue in the post-discharge phase(20,26). Interventions should be targeted according to the manifestations. Regarding physical and pulmonary rehabilitation, the beginning of an early program contributes to the overall optimization of the patient, shortening the length of stay in the ICU, in addition to its clinical and functional sequelae(27-31).

The proposed outpatient and home rehabilitation programs range from 6 to 12 weeks after discharge, with individualized and dynamic care, starting with low-intensity physical exercises and progressing according to the patient’s tolerance and adaptation, always with monitoring of oxygen saturation and fatigue(23,32). This study aimed to identify in the scientific literature the effects of hospitalization on the functional status and health-related quality of life (HRQoL) of patients with complications from COVID-19.

**METHODS**

**Research strategy and selection of studies**

This study is characterized as a literature review. The search for scientific articles was performed in the MEDLINE database (accessed by PubMed) from October 2020 to March 2022. A search strategy that combines MeSH terms and free words was adopted, according to Figure 1. This study followed the methodological guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) represented in Figure 2.

**Figure 1.** Search strategy of PubMed

| Search | Query |
|--------|-------|
| #1     | "COVID-19"[Mesh Terms] |
| #2     | "SARS-CoV-2"[Mesh Terms] |
| #3     | "COVID-19"[Title/Abstract] OR "SARS-CoV-2"[Title/Abstract] |
| #4     | #1 OR #2 OR #3 |
| #5     | "critical care"[Mesh Terms] |
| #6     | "Intensive Care Units"[Mesh Terms] |
| #7     | "post-acute COVID-19 syndrome"[Supplementary Concept] |
| #8     | "intensive care unit"[Title/Abstract] OR "ICU"[Title/Abstract] OR "critical illness"[Title/Abstract] OR "ventilator"[Title/Abstract] OR "Intensive care center"[Title/Abstract] OR "Mechanical ventilation"[Title/Abstract] OR "ARDS"[Title/Abstract] OR "acute respiratory distress syndrome"[Title/Abstract] OR "intensive care unit acquired weakness"[Title/Abstract] OR "post-intensive care syndrome"[Title/Abstract] OR "chronic fatigue syndrome"[Title/Abstract] "Hospital"[Title/Abstract] OR "Hospitalization"[Title/Abstract] OR "Hospital interment"[Title/Abstract] OR "Hospital Admission"[Title/Abstract] OR "Nursery"[Title/Abstract] |
| #9     | "Functional assessment"[Title/Abstract] OR "Physical assessment"[Title/Abstract] OR "Physical therapy evaluation"[Title/Abstract] OR "Musculoskeletal evaluation"[Title/Abstract] OR "Functional measurements"[Title/Abstract] "Physical measurements"[Title/Abstract] OR "Quality of life"[Title/Abstract] OR "Health-related quality of life"[Title/Abstract] OR "Capacity of exercise"[Title/Abstract] |
| #10    | #5 OR #6 OR #7 OR #8 OR #9 |
Eligibility Criteria

For the composition of this study, cross-sectional observational and prospective and retrospective cohort studies were eligible, which included adult patients (≥ 18 years), of any race and gender, with a positive diagnosis for COVID-19 through laboratory tests and who received were hospitalized in hospital environments, both wards and ICUs. Only complete articles published between 2019 and 2022 in the PubMed database and in English were included. In addition, it was also observed that the studies met the following criteria: to assess the functional status and quality of life after hospital discharge through scales, tests and assessment instruments with reliability reported in the literature. Articles published in the gray literature, research protocols, comments, editorials, consensus reports, articles with missing data on physical assessment or quality of life were excluded.

Outcomes

1. Symptom assessment: modified Medical Research Committee Questionnaire (mMRC); Dyspnoea Medical Research Council (MRC) dyspnoea score; Post-COVID-19 Functional Status (PCFS) Scale; Saint George’s Respiratory Questionnaire (SGRQ); University of California San Diego Shortness of Breath Questionnaire (UCSD).

2. Functional exercise capacity: 6 minute walk test (6MWT); incremental and endurance shuttle walk tests (ISWT and ESWT); 1-min sit-to-stand test (1-MSTST).

3. Health-related quality of life (HRQL): Short Form Health Survey 12-item (SF-12); Short-Form Health Survey 36 (SF-36), EuroQol 5 Dimension 5 Level (EQ-5D-5L), EuroQol 5 Dimension 3 Level (EQ-5D-3L); EuroQol visual analogue scale (EQ-VAS).

Data extraction

The phases of article selection were carried out independently by two reviewers and, in cases of disagreement, they were resolved by consensus between two authors (MCO and MEML). In the title and abstract selection phase, a standardized Microsoft Excel spreadsheet was filled out, containing the reason for the inclusion and exclusion of each article. After this procedure, the full texts were read, and studies that met the criteria were included, regardless of the type of study.
## Table 1. Functional status outcomes and health-related quality of life in COVID-19 survivors

| Author(s), publication year | Study design | Country | Sample size N | Male/ Female N (%) | Age (years) | Follow-up period after hospital discharge (months) | Hospitalization period (HP)/ HP ICU/ HP IMV (days) | Hospitalization ICU/ IMV N (%) | Outcomes | Results Mean (SD) or Median (IQR) |
|-----------------------------|--------------|---------|---------------|--------------------|-------------|--------------------------------------------------|--------------------------------------------------|--------------------------------|-----------|--------------------------------|
| Betschar et al. 2021[33]    | Prospective cohort | Switzerland | 43 | 30 (70%)/ 13 (30%) | 60 ± 14 | 0, 3 and 12 | 10 ± 9/ N/A/ N/A | 43 (100%)/ N/A | 6MWD m | 529 ± 118 | 578 ± 129 | 563 ± 124 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | 6MWD % pred | 94 ± 21 | 102 ± 21 | 100 ± 22 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | mMRC ≥2 | 9 (24%) | 5 (13%) | 7 (17%) |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | PCFS ≥2 | 75 (16) | 82 (16) | 75 (19) |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | EQ-VAS | 14 (44%) | 10 (26%) | 12 (29%) |
| Carenzo, et al. 2021[34]   | Prospective cohort | Italy | 47 | 37 (79%)/ 10 (21%) | 59 ± 10 | 2 and 6 | 29 (19-35)/ 15 (9-19)/ 12 (6-17) | 47 (100%)/ 47 (100%) | 6MWD m | 470 (406-516) | 83 (67-99)% | 85 [77,5-90] |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | 6MWD % pred | 161 ± 161 | 160 ± 160 | 160 ± 160 |
| Erber, et al. 2021[35]     | Prospective cohort | Germany | 18 | 14 (77,8%)/ 4 (22,2%) | 54 ± 12.3 | 1 and 7 | 21,5 (8-71)/ 10 (1-71) | 18 (100%)/13 (72,2%) | SF-36 | 16,1 ± 31,9 | 54,2 ± 43,7 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | RP | 33,3 ± 31,7 | 51,9 ± 36,0 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | PF | 69,5 ± 17,6 | 70,6 ± 17,7 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | MH | 58,3 ± 47,4 | 66,7 ± 40,8 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | RE | 45,0 ± 11,9 | 59,6 ± 20 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | SF | 51,8 ± 13,5 | 45,2 ± 11,1 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | VT | 64,6 ± 22,1 | 61,9 ± 26,7 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | GH | 35,4 ± 22,5 | 19,3 ± 18,5 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | symptoms SGRQ | 21,9 ± 14,7 | 16,7 ± 14,6 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | impact SGRQ | 161 ± 161 | 160 ± 160 | 160 ± 160 |
| Gianella, et al. 2021[36]  | Prospective, cross-sectional | Switzerland | 39 | 30 (76,9%)/ 9 (23,1%) | 62,5 (3-71) | 3 | 15 (12-22)/ N/A/ N/A | 10 (25,6%)/ 7 (17,9%) | 6MWT m | 539,3 ± 102,8 | 6 (15,4%) | 16 (15,4%) |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | mMRC (≥ 2) | 21,7 ± 18,6 | 27,1 ± 24,1 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | symptoms SGRQ | 9,6 ± 17,9 | 31 ± 1,6 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | activity SGRQ | 64,6 ± 22,1 | 61,9 ± 26,7 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | impact SGRQ | 35,4 ± 22,5 | 19,3 ± 18,5 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | SF-12 | 21,9 ± 14,7 | 16,7 ± 14,6 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | Abnormal SF-12 | 539,3 ± 102,8 | 6 (15,4%) | 16 (15,4%) |
| Hazarika, et al. 2021[37]  | Prospective, cross-sectional | India | 74 | 48 (64,9%)/ 26 (35,1%) | 50 ± 13.7 | 3 | N/A/ 10 (8-14,2)/ N/A | N/A | 6MWT m | 480.14 ± 85.7 |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | SF-12 | 51,53 (41,9-54,92) | 57,38 (54,69,59,82) |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | PCS | 2 (2-2) |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | MCS | 1 (1-3); |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | Dyspnoea MRC | 18 (52,9%) | 14 (41,2%) |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | PCFS | 0,79 (0,65-0,86) | 75 (59-90) |
| Johnsen, et al. 2021[38]   | Prospective, cross-sectional | Denmark | 34 | 21 (62%)/ 13 (38%) | 57 ± 10 | 3 | 13,3 ± 21,9/ N/A/ N/A | N/A/ 1 (2,9%) | 1-MSTST | 51,53 (41,9-54,92) | 57,38 (54,69,59,82) |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | >25th percentile: | 2 (2-2) |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | ≤25th percentile: | 18 (52,9%) | 14 (41,2%) |
|                            |              |         |               |                    |             |                                                  |                                                  |                                | Index value | 0,79 (0,65-0,86) | 75 (59-90) |
| Study                  | Study Design       | Country | Sample Size | Mean Age | Mean BMI | Gender Distribution | Follow-Up | Expected Changes |
|-----------------------|--------------------|---------|-------------|----------|----------|---------------------|-----------|------------------|
| Labarca, et al. 2021  | Prospective, cross-sectional | Chile   | 42          | 26 (61.9%) | 48.7 ± 10.6 | 4 (9%) / 16 (38.1%) | 12/40     | 59.5% / 14.8/ 10.3 ± 8.3/ 10.2 ± 7.5/ 25 (59.5%) |
| Lombardi et al. 2021  | Prospective, cross-sectional | Italy   | 87          | 58 (67%)  | 58 ± 13   | 1 (100%) / 29 (33%) | 1/6       | 15 (17%) / 6 (7%) |
| Shah, et al. 2021     | Prospective cohort  | Canada  | 73          | 44 (60%)  | 65 (53-72) | 3 and 6 (40%)       | N/A       | N/A              |
| Zhang, et al. 2021    | Retrospective cohort | China   | 40          | 21 (52.5%) | 57 (40-68) | 8 (100%) / 19 (47.5%) | N/A       | 2 (0.8%) / 0 (0.0%) |
| Zhao, et al. 2021     | Prospective cohort  | China   | 94          | 54 (57.4%) | 48.11 ± 6.3 | 12 (100%) / 40 (42.6%) | N/A       | 15 (11.7%) / N/A  |
| Demoule, et al. 2022  | Prospective cohort  | France  | 94          | 67 (71%)  | 63 (49-70) | 2 and 12 (29%)       | N/A/30    | 94 (100%) / 73 (78%) |
| Liao, et al. 2022     | Prospective, cross-sectional | China   | 303         | 59 (19.5%) | 39.0 (33,0-48,0) | 12 (100%) / 244 (80.5%) | N/A       | N/A              |
| Magdy, et al. 2022    | Prospective cohort  | Egypt   | 85          | 48 (56.5%) | 34.6 ± 9.9  | 3 and 6 (43.5%)       | 18.5 ± 5.6/ N/A/ N/A | 25 (29.4%) / 6 (7%) |

**Expected Changes**

- EQ-VAS: Change in HRQoL >10%
- 6MWT m: 513.5 ± 114.5
- 6MWT % pred: 92.3 ± 112.5
- SF-12: 39.1 ± 12.1
- PCS: 89.0 ± 9.0
- HRQoL at baseline: 65.3 ± 20.9
- HRQoL final: 31 (73.8%)
- Change in HRQoL: 6MWT m 500 ± 88
**DISCUSSION**

Following up on COVID-19 survivors after hospital discharge is now the new challenge of the pandemic, as the extent of the functional and psychosocial damage that persists after infection is still unclear. It is believed that permanent sequelae will be more pronounced in patients who were admitted to the ICU and for this reason, there is a need for studies that describe the outcomes of COVID-19 infection and possible ways to identify patients with compromised health condition were included. It is worth mentioning that several specialists recognized the importance of creating measures to obtain results that will help in identifying the needs of these patients, in order to direct, plan and conduct more appropriate interventions and resources.

A systematic review mapped physical performance assessments in patients with COVID-19 that can help professionals in the structuring of post-discharge consultations and in the creation of outpatient and/or home rehabilitation programs\(^{(48,49)}\). As noted in ARDS, an increase in the incidence of ICUAW can be anticipated in both the short and long term. According to the literature, patients with septic conditions in intensive care develop a loss of up to 20% of the muscle mass of the thighs in the first week of hospitalization, and this time of bed rest is enough to cause a decline in muscle strength by up to 30%, adding an additional 20% loss of remaining strength every seven days. Healthy people, when submitted to immobilization, lose about 14% of muscle mass and 16% of muscle strength\(^{(50)}\).

The inflammatory process generated by the infection associated with prolonged rest leads to muscle loss that is up to 10 times more pronounced than in healthy individuals, directly reflecting the functional capacity of patients\(^{(1)}\). The most frequent exercise functional capacity measure observed in this review was the 6MWT, probably due to its good reliability, low cost, simple and safe application to measure exercise tolerance in patients with cardiorespiratory changes, which can be performed in a flat and rigid space of 30 meters. This test correlates very...
well with the morbidity and mortality rate\(^{(51,52)}\). Thus, it is an objective tool for measuring exercise capacity, valid for expressing the degree of disability, observing exercise limitations and formulating the basis for a subsequent rehabilitation program\(^{(48,53)}\).

In the study by Wu et al. (2021), patients hospitalized for COVID-19 showed improvements in dyspnea and exercise capacity in a cohort followed for 12 months. The median distance traveled on the 6MWT significantly increased from 535 m (IQR 490–565) at 3 months to 585 m (552–626) at 6 months (p<0.0001). On the other hand, dyspnea symptoms evaluated by the mMRC scale were very frequent in patients at 3 months, of these 67 (81%) had the mMRC score of at least 1 and five (6%) patients had an mMRC score of at least 3\(^{\%}\). The number of patients with various levels of dyspnea symptoms progressively and significantly reduced at 6 months, 9 months and 12 months\(^{(54)}\).

According to the study by Liao et al. (2022), 303 healthcare workers from China were evaluated for the long-term consequences of COVID-19. A comparison of patients with mild/moderate illness and those with critical/severe illness showed a shorter walking distance at 6MWT (549.50, IQR 514.0–582.0 vs. 564.0, 525.0–603, 0). The median was found below the lower limit of normality in 19.4%. The SGRQ and mMRC scores of survivors, especially those with critical/severe illness, were also significantly higher than those of the normal population\(^{(45)}\).

Dyspnea induced by ADLs or exercise was also frequently measured mainly by mMRC and Dyspnea MRC, which has been widely used in individuals with sequelae of COVID-19. These scales are traditionally used and cited in the international literature mainly because they are easy to apply and understand\(^{(65)}\).

The PCFS scale is also a tool that was adapted and validated to assess the impact of COVID-19 on functional status as it covers most limitations in ADLs, but this should be a supporting measure to the other instruments, not a substitute\(^{(56,57)}\).

Existing data demonstrate that patients requiring intensive care or invasive mechanical ventilation (IMV) are at high risk of developing PICS. This is a phenomenon commonly observed in cases recovered from the ICU and among different age groups, being constantly described as prolonged disability resulting from muscle changes, lethargy, pain and dyspnea\(^{(58,59)}\). Another study observed that the functional status measured by PCFS was shown to be reduced in 87 (47.5%) patients in the sample. Patients who went to the ICU reported a greater reduction in their functional status compared to patients who did not go to the ICU (81.3% vs 40.4%, p<0.001). Two degrees of reduction in functional status were also observed in ICU patients in relation to the others (56.3% vs 6%, p<0.001). Limitation in ADLs (grade II-IV) was reported in 56.4% of patients who went to the ICU compared with 17.9% in patients who were not admitted to the ICU (p<0.001). Dyspnea on minor exertion was reported in only 19 patients (10.4%), however ICU patients reported dyspnea more frequently compared to non-ICU patients (37.5% vs 4.6%, p<0.001)\(^{(60)}\).

In a study with 444 patients infected with COVID-19 evaluated between four and eight weeks after hospital discharge, it was shown that 80% of recovered cases had varying degrees of functional restrictions, ranging from insignificant (63.1%), mild (14.4 %), moderate (2%) to severe (0.5%) based on the PCFS scale\(^{(58)}\).

Another study carried out six months after discharge, involving 91 critically ill patients admitted to the ICU, demonstrated a reduction in the functional status on the PCFS scale, in 57 (63%) patients. Initial period after discharge and 41 (45%) reported persistent functional limitations (grade II-IV). A decrease in HRQoL was also observed in\(^{(61)}\) patients (67%). The distributions of patients with moderate to severe problems across the five dimensions of the EQ-5D-3L were mobility (56%), usual activities (37%), pain/discomfort (48%), and anxiety/depression (46%)\(^{(62)}\).

Demoule et al. (2022) observed that even twelve months after ICU discharge for COVID-19 and subsequent rehabilitation, a considerable proportion of patients reported changes in HRQoL, dyspnea, and symptoms that were not present before admission, these factors associated with a worse rate of HRQoL at 12 months can help to identify patients at risk\(^{(44)}\).

Advanced age, male gender, smoking, body mass index, need and length of hospitalization, use and time of MV during ICU stay, need and length of ICU stay are often associated with decreased health-related quality of life., decreased functional status at 6 months after ICU admission, or both\(^{(60-62,44)}\). Other scales that categorize individuals according to health-related HRQoL were the SF-12, SF-36, EQ-5D-5L and the EQ-VAS. In a study involving 18 patients with COVID-19 admitted to the ICU, followed up prospectively, a median of 36, 75.5,
122 and 222 days after discharge was observed. The HRQoL assessment showed that physical functionality was reduced, as well as the impact incidence of the SGRQ and symptom scores, which improved over time, but when compared to the reference groups, they remained impaired\(^{(35)}\).

In the SF-36 assessment of the HRQL, the greatest changes in the initial visit were in the domain 'function limitation due to physical problems' (16.1 ± 31.9) and physical functioning (33.3 ± 31.7). When compared with predicted values for the healthy population, impairments in the domains of social functioning (60.7 ± 27.2), role limitations due to emotional problems (58.3 ± 47.4) and general health (60.7 ± 47.4) 27.2 were more pronounced. While impairment in the general health dimension remained impaired during follow-up, limitations due to physical problems, as well as impairment in physical functioning, also decreased significantly in relation to reference values\(^{(35)}\).

The study by Gianella et al (2021) involving 39 patients who were hospitalized due to SARS-CoV-2 pneumonia evaluated three months after hospital discharge. In this study, it was observed that 31 patients (79.5\%) reported a poor health perception due to respiratory symptoms assessed by the SGRQ and that all 39 patients showed a decrease in HRQoL measured by the SF-12. In this same study, both the 6MWD and the sensation of dyspnea measured by the mMRC were also different according to the division of groups based on chest computed tomography\(^{(36)}\).

The American Thoracic Society (ATS) and European Respiratory Society (ERS) international task force suggests that the follow-up of a patient with COVID-19 after hospitalization should include a robust physical and psychosocial assessment allowing the identification of possible sequelae and persistent symptoms\(^{(39)}\). A set of baseline results consistently evaluated using accurate measurement instruments allows essential data to be pooled and draw credible conclusions. With that, it was possible to perceive that in all the studies used for the composition of the sample of this research, the result of the evaluations presented, in a certain way, the same pattern: the decline of the functional status, mainly increase of the fatigue; decreased muscle strength, balance and mobility; impaired independence; consequently causing harm to HRQoL and functional capacity.

Thus, pre-existing data from patients surviving viral pneumonia and chronic obstructive pulmonary disease (COPD) indicate a variety of challenges that these patients may present. An acute inflammatory response in the lungs, in addition to some extrapulmonary manifestations, such as peripheral skeletal and respiratory muscle dysfunction, contribute to exercise intolerance\(^{(63-65)}\).

It is recommended that these post-COVID-19 patients, especially those who required hospitalization, have a formal assessment of physical capacity to identify unmet rehabilitation needs due to changes that continue to be present in physical functioning\(^{(36,60)}\). While initially COVID-19 was also considered a respiratory disease, it is now clear that it affects a variety of systems, making it unlikely that a one-dimensional physical training program will meet the needs of COVID-19 survivors.

There is still a small number of scientific studies in the literature and the absence of a standardization in the way of expressing the results, which limits and complicates the composition of a systematic review. In view of the studies presented, it can be observed that there was a decrease in the functional status and HRQoL of hospitalized patients after COVID-19. Therefore, it is necessary to develop more studies properly designed to verify the real dimension of the repercussions on the physical and psychosocial health of these patients and, consequently, how rehabilitation can minimize these sequelae.

**CONCLUSION**

With this literature review, it can be concluded that patients hospitalized for complications of COVID-19 showed a significant decline in functional status and health-related quality of life. However, updates are needed to characterize the clinical signs, functional variables and HRQoL in COVID-19 survivors, in addition to studies that guide the most effective approach to assess and rehabilitate these patients.

**Authors’ contribution:** MCO, and LVFO contributed to the elaboration of the design of the study; MCO, MEML, MMC, JPRA, RSM, LFRJO, ALF development of the study and data acquisition. MCO, VVCBM, BNS, ERPP, SKAS, TLG contributed to article design and data tabulation. MCO, MEML, MMC, JPRA, RSM, LFRJO, ALF contributed to the critical review, correction and approval of the final version.

**Financial support:** nothing to declare.

**Conflict of interest:** the authors declare that they have no conflict of interest.
REFERENCES

1. Poulsen JB. Impaired physical function, loss of muscle mass and assessment of biomechanical properties in critical ill patients. Dan Med J. 2012;59(11):1–21.

2. Wunsch H, Angus DC, Harrison DA, Collange O, Fowler R, Hoste EA, et al. Variation in critical care services across North America and Western Europe. Crit Care Med. 2008;36(10):2787–93.

3. Modrykamiern AM. The ICU follow-up clinic: a new paradigm for intensivists. Respir Care. 2012;57(5):764–72.

4. Grasselli G, Zanigrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574–1581.

5. Harvey MA, Davidson JE. Post-intensive care syndrome: right care, right now…and later. Crit Care Med. 2016;44(2):381–5.

6. Desai SV, Law TJ, Needham DM. Long-term complications of critical care. Crit Care Med. 2011;39(2):371–79.

7. Hopkins RO, Weaver LK, Collingridge D, Parkinson RB, Chan KJ, Orme Jr JF. Twoyear cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2005;171(4):340–47.

8. Rawal G, Yadav S, Kumar R. Post-intensive care syndrome: An overview. J Transl Intern Med. 2017;5(5):90–2.

9. Nakanishi N, Liu K, Kawakami D, Kawai Y, Morisawa T, et al. Post-Intensive Care Syndrome and Its New Challenges in Coronavirus Disease 2019 (COVID-19) Pandemic: A Review of Recent Advances and Perspectives. J Clin Med. 2021 Aug 28;10(17):3870.

10. Daste C, Ficarra S, Dumitrache A, et al. Post-intensive care syndrome in patients surviving COVID-19. Ann Phys Rehabil Med. 2021;64(6):101549. doi:10.1016/j.rehab.2021.101549

11. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampa E, Villamizar-Peña R, Holguín-Rivera Y, Escalera-Anteza JP, et al. Clinical, laboratory, and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;101623.

12. Hopkins RO, Weaver LK, Collingridge D, Parkinson RB, Chan KJ, Orme Jr JF. Twoyear cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2005;171(4):340–47.

13. Diaz Ballve LP, Dargains N, Urrutia Inchausteugi JG, Bratos A, Milagros Percaz M de los, Bueno Ardariz C, et al. Weakness acquired in the intensive care unit. Incidence, risk factors and their association with inspiratory weakness. Observational cohort study. Rev Bras Ter Intensiva. 2017;29(4):466–75.

14. Jennings G, Monaghan A, Xue F, Mockler D, Romero-Oruño R. A Systematic Review of Persistent Symptoms and Residual Abnormal Functioning following Acute COVID-19: Ongoing Symptomatic Phase vs. Post-COVID-19 Syndrome. J Clin Med. 2021;10(24):5913.

15. Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. Post-COVID-19 Syndrome: The Persistent Symptoms at the Post-viral Stage of the Disease. A Systematic Review of the Current Data. Front Med (Lausanne). 2021;8:653516.

16. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebollole PA, Cuapia O, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Scientific reports.2021;11(1), 1–12.

17. Sanchez-Ramirez DC, Normand K, Zhaoyun Y, Torres-Castro R. Long-term impact of COVID-19: A systematic review of the literature and meta-analysis. Biomedicines. 2021;9(8),900.

18. Griffiths J, Hatch RA, Bishop J, Morgan K, Jenkinson C, Cuthbertson BH, et al. An exploration of social and economic outcome and associated health-related quality of life after critical illness in general intensive care unit survivors: a 12-month follow-up study. Crit Care. 2013;17(3):R100.

19. de Jonghe B, Lacherade J-C, Sharshar T, Outin H. Intensive care unit-acquired weakness: risk factors and prevention. Crit Care Med. 2009;37(10):S309–15.

20. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2020; Kress JP, Hall JB. ICU-acquired weakness and recovery from critical illness. N Engl J Med. 2014;370(17):1626–35.

21. Mendez-Tellez PA, Nusr R, Needham DM, Feldman D. Early Physical Rehabilitation in...
the ICU: A Review for the Neurohospitalist. The Neurohospitalist. 2012;2(3):96–105.

23. Woods J, Hutchinson NT, Powers SK, Roberts WO, Gomez-Cabrera MC, Radak Z, et al. The COVID-19 Pandemic and Physical Activity. Sport Med Heal Sci. 2020;

24. Ely EW. The ABCDEF bundle: science and philosophy of how ICU liberation serves patients and families. Crit Care Med. 2017;45(2):321-30.

25. Marra A, Ely EW, Pandharipande PP, Patel MB. The ABCDEF bundle in critical care. Crit Care Clin. 2017;33(2):225–43.

26. Belli S, Balbi B, Prince I, Cattaneo D, Masocco F, Zaccaria S, et al. Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation. Eur Respir J. 2020;56(4).

27. Denely H, Elliott D. Strategies for post ICU rehabilitation. Curr Opin Critical Care. 2012;18(5):503–8.

28. Gloeckl R, Leiiti D, Jarosch I, Schneeberger T, Nell C, Stenzel N, et al. Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study. ERJ Open Res. 2021 May 31;7(2):00108-2021.

29. Puchner B, Sahanic S, Kirchmair R, Pizzini A, Sonnweber B, Wöll E et al. Beneficial effects of multi-disciplinary rehabilitation in postacute COVID-19: an observational cohort study. Eur J Phys Rehabil Med. 2021 Apr;57(2):189-198.

30. Everaerts S, Heyns A, Langer D, Beyens H, Hermans G, Troosters T, et al. COVID-19 recovery: benefits of multidisciplinary respiratory rehabilitation. BMJ Open Respir Res. 2021 Sep;8(1):e000837.

31. Gobbi M, Bezzoli E, Ismelli F, Trotti G, Cortellezzi S, Meneguzzo F, et al. Skeletal Muscle Mass, Sarcopenia and Rehabilitation Outcomes in Post-Acute COVID-19 Patients. J Clin Med. 2021 Nov 29;10(23):5623.

32. Santana AV, Fontana AD, Pitta F. Pulmonary rehabilitation after COVID-19. J Bras Pneumol. 2021 Feb 42;24:47(1):e20210034.

33. Betschart M, Rezek S, Unger I, Ott N, Beyer S, Böni A, et al. One year follow-up of physical performance and quality of life in patients surviving COVID-19: a prospective cohort study. Swiss medical weekly. 43. 2021;151(43-44).

34. Carenzo L, Protti A, Dalla Corte F, Aceto R, Iapichino G, Milani A, et al. Short-term health-related quality of life, physical function and psychological consequences of severe COVID-19. Annals of Intensive Care. 2021;11(1):1–8.

35. Erber J, Wiebner JR, Zimmermann GS, Barthel P, Burian E, Lohöfer F, et al. Longitudinal Assessment of Health and Quality of Life of COVID-19 Patients Requiring Intensive Care—An Observational Study. J Clin Med. 2021;10(23):5469.

36. Gianella P, Rigamonti E, Marando M, Tamburrello A, Grazioli Gauthier L, Argentieri G, et al. Clinical, radiological and functional outcomes in patients with SARS-CoV-2 pneumonia: a prospective observational study. BMC Pulm Med. 2021;21(1):1–7.

37. Hazarika A, Mahajan V, Kajal K, Ray A, Singla K, Sehgal IS, et al. Pulmonary Function, Mental and Physical Health in Recovered COVID-19 Patients Requiring Invasive Versus Non-invasive Oxygen Therapy: A Prospective Follow-Up Study Post-ICU Discharge. Cureus. 2021;13(9).

38. Denehy L, Elliott D. Strategies for post ICU rehabilitation. Curr Opin Critical Care. 2012;18(5):503–8.

39. Gloeckl R, Leiiti D, Jarosch I, Schneeberger T, Nell C, Stenzel N, et al. Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study. ERJ Open Res. 2021 May 31;7(2):00108-2021.

40. Puchner B, Sahanic S, Kirchmair R, Pizzini A, Sonnweber B, Wöll E et al. Beneficial effects of multi-disciplinary rehabilitation in postacute COVID-19: an observational cohort study. Eur J Phys Rehabil Med. 2021 Apr;57(2):189-198.

41. Everaerts S, Heyns A, Langer D, Beyens H, Hermans G, Troosters T, et al. COVID-19 recovery: benefits of multidisciplinary respiratory rehabilitation. BMJ Open Respir Res. 2021 Sep;8(1):e000837.

42. Gobbi M, Bezzoli E, Ismelli F, Trotti G, Cortellezzi S, Meneguzzo F, et al. Skeletal Muscle Mass, Sarcopenia and Rehabilitation Outcomes in Post-Acute COVID-19 Patients. J Clin Med. 2021 Nov 29;10(23):5623.

43. Santana AV, Fontana AD, Pitta F. Pulmonary rehabilitation after COVID-19. J Bras Pneumol. 2021 Feb 42;24:47(1):e20210034.
44. Demoule A, Morawiec E, Decavele M, Ohayon R, Malrin R, Galarza-Jimenez MA, et al. Health-related quality of life of COVID-19 two and 12 months after intensive care unit admission. Annals of Intensive Care. 2022;12(1):1–11.

45. Liao T, Meng D, Xiong L, Wu S, Yang L, Wang S, et al. Long-Term Effects of COVID-19 on Health Care Workers 1-Year Post-Discharge in Wuhan. Infect Dis Ther. 2022;11(1):145–63.

46. Magdy DM, Metwally A, Tawab DA, Hassan SA, Makboul M, Farghaly S. Long-term COVID-19 effects on pulmonary function, exercise capacity, and health status. Annals of Thoracic Medicine. 2022;17(1):28.

47. Vejen M, Hansen EF, Al-Jarah BNI, Jensen C, Thaning P, Jeschke KN, et al. Hospital admission for COVID-19 pneumonitis–long-term impairment in quality of life and lung function. European Clinical Respiratory Journal. 2022;9(1):2024735.

48. Simonelli C, Paneroni M, Vitacca M, Ambrosino N. Measures of physical performance in COVID-19 patients: a mapping review. Pulmonology. 2021 Nov-Dec;27(6):518–528.

49. Spruit MA, Holland AE, Singh SJ, Tonia T, Wilson KC, Troosters T. COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society-and American Thoracic Society-coordinated international task force. Eur Respir J. 2020;56(6).

50. Herridge MS, Tansey CM, Matté A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364:1293–304.

51. ATS Statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111–117.

52. Pinto-Plata VM, Cote C, Cabral H, et al. The 6-minute walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004; 23: 28–33.

53. Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax. 2003;58(9):752–6.

54. Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, Ni F, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021 Jul;9(7):747-754.

55. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581-6.

56. Machado FV, Meys R, Delbressine JM, Vaes, AW, Goertz YM, van Herck M, et al. Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19. Health and quality of life outcomes.2021; 19(1), 1-10.

57. Klok FA, Boon GJ, Barco S, Endres M, Geelhoed JM, Knauss S, et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. European Respiratory Journal; 2020; 56(1).

58. Smith JM, Lee AC, Zeleznik H, Coffey Scott JP, Fatima A, Needham DM, et al. Home and community-based physical therapist management of adults with post-intensive care syndrome. Phys Ther. 2020;100:1062–73.

59. Ohtake PJ, Lee AC, Scott JC, Hinman RS, Ali NA, Hinkson CR, et al. Physical impairments associated with post-intensive care syndrome: Systematic review based on the world health organization's international classification of functioning, disability and health framework. Phys Ther. 2018;98:631–45.

60. Taboada M, Cariñena A, Moreno E, Rodriguez N, Domínguez MJ, Casal A, et al. Post-COVID-19 functional status six-months after hospitalization. J Infect. 2021 Apr;82(4):e31-e33.

61. Mohamed Hussein AA, Saad M, Zayan HE, Abdelsayed M, Moustafa M, Ezzat AR, et al. Post-COVID-19 functional status: Relation to age, smoking, hospitalization, and previous comorbidities. Ann Thorac Med. 2021 Jul-Sep;16(3):260-265.

62. Taboada M, Moreno E, Cariñena A, Rey T, Pita-Romero R, Leal S, et al. Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients. Br J Anaesth. 2021 Mar;126(3):e110-e113.

63. Gandotra S, Lovato J, Case D, Bakhr RN, Gibbs K, Berry M, et al. Physical function trajectories in survivors of acute respiratory failure. Ann Am Thorac Soc. 2019;16(4):471–7.
64. Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, et al. Long-term cognitive impairment after critical illness. N Eng J Med. 2013;369(14):1306–16.

65. Parker AM, Sricharoenchai T, Raparla S, Schneck KW, Bienvenu OJ, Needham DM. Posttraumatic stress disorder in critical illness survivors: a metaanalysis. Crit Care Med. 2015;43(5):1121–9.

66. Santana AV, Fontana AD, Pitta F. Pulmonary rehabilitation after COVID-19. J Bras Pneumol. 2021 Feb 24;47(1):e20210034.